Study on the mechanism of Danshen-Guizhi drug pair in the treatment of ovarian cancer based on network pharmacology and in vitro experiment

Chongzhen Qin¹,*, Menglin Wu¹,*, Xinru Wang¹, Wenda Zhang¹, Guangzhao Qi¹, Na-Yi Wu², Xiaoting Liu³, Yaoyao Lu¹, Jingmin Zhang¹ and Yuna Chai¹

¹ The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
² Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
³ The Second People’s Hospital of Hunan Province, Changsha, China

* These authors contributed equally to this work.

ABSTRACT
Our study aims to explore the active components and mechanisms of the Danshen-Guizhi drug pair in treating ovarian cancer by network pharmacology and in vitro experiment. The “component-target-pathway” diagram of the Danshen-Guizhi drug pair was established by network pharmacology, and the effective active components, important targets as well as potential mechanisms of the Danshen-Guizhi drug pair were analyzed. The predicted results were verified by molecular docking and in vitro experiments. The main active components of the Danshen-Guizhi drug pair in the treatment of ovarian cancer are salviolone, luteolin, β-sitosterol and tanshinone II A. The main core target is PTGS2. The pathways involved mainly include the cancer pathway, PI3K-Akt signaling pathway, and IL-17 signaling pathway. The molecular docking results showed that salviolone and tanshinone II A had good binding ability to the target. The expression of PTGS2 mRNA and PGE2 in ovarian cells were significantly inhibited by salviolone.

The mechanism of the Danshen-Guizhi drug pair in the treatment of ovarian cancer may be regulating cell proliferation, apoptosis and tumor immunity. This provides a theoretical basis for the clinical development and application of the Danshen-Guizhi drug pair.

INTRODUCTION
Ovarian cancer is one of the most common gynecologic malignancies. Its incidence ranks third in female reproductive system malignant tumors, after cervical cancer and uterine cancer (Hunn & Rodriguez, 2012). The early symptoms of ovarian cancer are unobvious, and late symptoms are untypical, the recurrence rate and mortality of ovarian cancer is the first in all kinds of gynecological tumors (Gaona-Luviano, Medina-Gaona & Magana-
Perez, 2020). The treatment of ovarian cancer is mainly the comprehensive application of surgery and chemotherapy. However, surgical treatment has relatively large physical damage to patients, and there will be recurrence or serious complications, and platinum drug resistance is also a major problem in the treatment of ovarian cancer (McMullen, Madariaga & Lheureux, 2020).

Many clinical studies have shown that both a single Chinese herbal medicine and Chinese herbal formula for cancer treatment has been proved effective (Mao et al., 2017). It is reported that traditional Chinese medicine for the treatment of ovarian cancer plays an anti-cancer role mainly by affecting the proliferation and apoptosis of cancer cells, generating of tumor vessel and inhibiting the drug resistance of platinum chemotherapeutic drugs (Sun et al., 2020). Salvia miltiorrhiza Bunge (Radix Salviae, Danshen) was firstly recorded in Shennong’s Herbal Classics, which is a popular component of many traditional Chinese medicines. Previous studies have shown that the effective active ingredients of Danshen play a role in the development of ovarian cancer (Zhou et al., 2020; Wang et al., 2020; Yang et al., 2018). The water-soluble components of Danshen can promote blood circulation and remove blood stasis, and fat-soluble components have anti-inflammatory, antibacterial, antioxidant as well as anti-tumor effects (Su et al., 2015). Tanshinone, the fat-soluble component of Danshen, has antiproliferative effects on ovarian cancer cells by promoting apoptosis and down-regulating cisplatin resistance genes (Jiao & Wen, 2011). Neolitsea cassia (L.) Kosterm (Cinnamomi Ramulus, Guizhi) was first found in Newly Compiled Materia Medica of the Tang Dynasty. It can sweat and relieve external syndromes, warm meridians, improve blood circulation, and relieve pain (Liu et al., 2020). Guizhi mainly contains cinnamic acid and cinnamic aldehyde, and can inhibit the growth of cancer cells (Reddy et al., 2016). The main active components ofDanshen and Guizhi can play a synergistic effect, and improve the efficacy of the two drugs, with effect of promoting blood circulation, dredging collaterals, tonifying qi (vital energy) and nourishing heart. Traditional Chinese medicine believes that the formation of ovarian cancer is due to blood stasis, the pathological mechanism is mainly the disharmony of qi and blood, qi stagnation and blood stasis, and then the formation of mass as proposed by Medical Required (Jiang & Lin, 2006). The Danshen-Guizhi drug pair can improve the blood circulation of patients, balance qi and blood, and remove blood stasis. However, its therapeutic mechanism has not been clearly clarified.

With the rapid development of bioinformatics, network pharmacology has become a new discipline, which mainly reveals the pharmacological mechanism of traditional Chinese medicine. The research and development mode has changed from the traditional “single target, high selective drug development, disease-single target-single drug” to “multi-direction pharmacology, drug action on biological networks, disease-multi-target-single drug”, which has promoted the modernization of traditional Chinese medicine (Zhang et al., 2013; Zhou et al., 2020). Network pharmacology is mainly to obtain disease-related targets from diseases by text mining, obtain effective components of drugs in traditional Chinese medicine compound for target prediction, construct drug-target-disease network, and then carry out network analysis to predict the disease mechanism.
In this study, the network pharmacology method was used to explore the mechanism of the Danshen-Guizhi drug pair in the treatment of ovarian cancer with multi-component, multi-target and multi-pathway, to provide a theoretical basis for the further development and utilization of the Danshen-Guizhi drug pair in clinical practice.

**MATERIALS AND METHODS**

**Screening of effective chemical component and collecting targets of Danshen-Guizhi drug pair**

The main effective components of the Danshen-Guizhi drug pair were collected from the TCMSP (https://tcmspw.com/tcmsp.php). All components of the drug pair were screened by TCMSP based on absorption, distribution, metabolism, and excretion (ADME), including oral bioavailability (OB), drug similarity (DL), and lipids-water partition coefficient (AlogP) (Lee et al., 2019). OB is the percentage of oral drugs absorbed into systemic circulation, DL represents the similarity between the active ingredients of Traditional Chinese medicine and drugs, AlogP is one of the binding forces between drugs and receptors, and the occurrence of drug pharmacokinetic process is related to the hydrophobicity of drugs (Liu et al., 2013). All components of the Danshen-Guizhi drug pair were screened under the following conditions: oral bioavailability (OB) $\geq 30\%$, drug-like property (DL) $\geq 0.18$, and lipid-water partition coefficient (AlogP) $\leq 5$ (Liu et al., 2016). The main active compounds of the Danshen-Guizhi drug pair and their respective protein targets were obtained, the collected targets were transformed into gene names in the Uniprot protein database (https://www.uniprot.org/uploadlists/), and invalid genes were deleted.

**Acquisition of disease-related targets**

Enter “Ovarian Cancer” in Genecards database (https://www.genecards.org/) and OMIM database (https://omim.org/) to search for potential therapeutic targets of ovarian cancer.

**Construction of PPI network and screening of core targets**

The ovarian cancer-related gene targets obtained in Genecards were crossed with the drug targets collected in TCMSP to obtain the potential targets for drug treatment of ovarian cancer, and the VENNY diagram was plotted. Then the intersection targets were imported into the STRING (https://www.string-db.org/) database to restrict the species to human (“Homo sapiens”), and the protein-protein interaction network function enrichment analysis was carried out to obtain the PPI network. The results were topologically analyzed by Cytoscape3.8.0 software plug-in for potential therapeutic targets, and PPI network diagram of potential therapeutic targets of the Danshen-Guizhi drug pair for ovarian cancer was constructed.

In order to explore the mechanism of the Danshen-Guizhi drug pair in the treatment of ovarian cancer, the obtained PPI of disease and drug were combined with the intersection network in Cytoscape3.8.0 software, and then the topology network was analyzed by Cytoscape3.8.0 software plug-in to screen the core targets.
Enrichment analysis of Danshen-Guizhi drug pair in the treatment of ovarian cancer

The Matescape database (http://metascape.org/gp/index.html#/main/step1) is a powerful online tool for gene enrichment analysis, which can be used for gene annotation and analysis resources. The potential targets of the Danshen-Guizhi drug pair in the treatment of ovarian cancer were input into the Matescape database, and the species was limited to "H. sapiens". $P < 0.01$ was set for enrichment analysis of GO molecular function, cell composition and KEGG pathway.

Danshen-Guizhi drug pair “component-target-pathway” network construction

The network diagrams of active components, targets and pathways of drugs were drawn by Cytoscape 3.8.0 software. The network topology parameters of active components and targets of drugs were analyzed by CytoScape 3.8.0 plug-in CytoNCA. The core targets and main active components of drugs were judged according to the network topology parameters of Degree, Betweenness and Closeness.

Molecular docking verification

The main components corresponding to the target protein were searched from the TCMSP database (https://tcmspw.com/tcmsp.php), downloaded and saved as Mol2 format. The “component-target-pathway” network of the Danshen-Guizhi drug pair was analyzed, and the core targets with degree greater than 20 were selected for docking. The corresponding PDB ID of the core targets was found in the PBD (http://www1.rcsb.org/) database and saved as pdb format. Then the target was dehydrated and hydrogenated to optimize ligand in Pymol (Ren et al., 2020). Finally, the molecular docking was performed by AutoDock software to calculate the binding ability of the main active components of the Danshen-Guizhi drug pair to the core targets.

MTS assay

SKOV3 cells and A2780 cells were seeded in 96-well plates at 100 μL/well (about $1 \times 10^4$), cultured at 37 °C in 5% CO$_2$ incubator for 24 h. Luteolin, salviolone, tanshinone IIA and β-sitosterol were added at concentrations 0, 10 or 20 μm. Luteolin, β-sitosterol and tanshinone IIA were obtained from Sigma (USA) and salviolone was obtained from Tianjin Wanxiang Hengyuan Technology Co., LTD. After incubation for 2 h, the cell vitality was detected by MTS kit (G3582; Promega, Madison, WI, USA), and the optical density was detected at 450 nm.

Detection of PTGS2 mRNA expression by qRT-PCR

Molecular docking results showed that the docking results of salvianone with seven main targets were the best. In order to further explore the role of salviolone in ovarian cancer, we detected the effect of salviolone on PTGS2 mRNA expression in ovarian cells. SKOV3 cells and A2780 cells were seeded in a 6-well plate and added with 0 and 20 μm of salviolone for 24 h. Cells were collected, total RNA was extracted, and PTGS2 mRNA
was quantitatively detected. Data were represented as the Mean ± SD of three independent experiments.

Detection of PGE2 expression by ELISA
SKOV3 cells were seeded in 6-well plates at 1 × 10^5 cells per well. Cells were incubated in serum-free medium. The cells were incubated with 0, 20 μM salviolone for 2 h. The cell supernatant was collected and PGE2 was measured by ELISA kit (ab133021; Abcam, Cambridge, UK). The absorbance (OD) of the sample was measured at 415 nm. The average value was calculated by three repeated experiments.

Statistical analysis
SPSS Statistics 20.0 and GraphPad Prism v8.0.2 were used for statistical analysis. The data are expressed as Mean ± SD. Student's t-test was used to analyze the difference in effect of luteolin, salviolone, β-sitosterol as well as tanshinone IIA on ovarian cancer cells, compared with the control group, and P < 0.05 was considered to be statistically significant.

RESULTS

Obtaining active components and potential targets of Danshen-Guizhi drug pair
Through searching the TCMSP database, 202 effective active ingredients of Danshen and 220 effective active ingredients of Guizhi were obtained. According to ADME, 54 effective active ingredients of Danshen and six effective active ingredients of Guizhi were obtained. A total of 916 targets of effective components of Danshen and 74 targets of Guizhi were obtained. After deleting duplicate targets, 60 effective active ingredients and 136 targets were obtained, as shown in Table 1. The collected targets were transformed into genes in the Uniprot database.

Acquisition of ovarian cancer-related targets
A total of 8,366 potential targets related to ovarian cancer were obtained by Genecards human gene database. According to the target targets with Score greater than the median, the potential targets for the treatment of ovarian cancer were determined. Finally, 1,119 therapeutic targets for ovarian cancer were obtained (Table S1).

Construction and analysis of PPI network
A total of 119 ovarian cancer-related gene targets obtained in Genecards were crossed with 136 drug targets, and 66 potential targets for drug treatment of ovarian cancer were obtained. VENNY map was drawn, as shown in Fig. 1. The PPI network was constructed by STRING software for 66 targets. The network nodes represent proteins, and the edges represent the combination of proteins and proteins. The number of nodes is 66,1109. Cytoscape 3.8.0 software was used to construct the PPI network diagram of potential targets for the treatment of ovarian cancer by the Danshen-Guizhi drug pair, and the depth of node color as well as the size of node were related to the degree value. Gene targets can be screened from the color of node size: PTGS1, TP53, PTGS2, AKT1, MAPK1, JUN,
| Medicine | MOL ID   | Sign | Main active ingredient                                                                 | OB(%) | DL(%) |
|----------|----------|------|----------------------------------------------------------------------------------------|-------|-------|
| Danshen | MOL001601| DS1  | 1,2,5,6-tetrahydrotanshinone                                                             | 38.75 | 0.36  |
|          | MOL001942| DS2  | isoimperatorin                                                                          | 45.46 | 0.23  |
|          | MOL002222| DS3  | sugiol                                                                                  | 36.11 | 0.28  |
|          | MOL002651| DS4  | Dehydrotanshinone II a                                                                  | 43.76 | 0.4   |
|          | MOL002776| DS5  | Baicalin                                                                                 | 40.12 | 0.75  |
|          | MOL000569| DS6  | digallate                                                                                | 61.85 | 0.26  |
|          | MOL000006| DS7  | luteolin                                                                                 | 36.16 | 0.25  |
|          | MOL007036| DS8  | 5,6-dihydroxy-7-isopropyl-1,1-dimethyl-2,3-dihydrophenanthren-4-one                     | 33.77 | 0.29  |
|          | MOL007041| DS9  | 2-isopropyl-8-methylphenanthrene-3,4-dione                                               | 40.86 | 0.23  |
|          | MOL007045| DS10 | 3α-hydroxytanshinoneIIa                                                                  | 44.93 | 0.44  |
|          | MOL007048| DS11 | (E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-benzofuran-4-yl]acrylic acid                   | 48.24 | 0.31  |
|          | MOL007049| DS12 | 4-methylenemiltirone                                                                    | 34.35 | 0.23  |
|          | MOL007050| DS13 | 2-(4-hydroxy-3-methoxyphenyl)-5-(3-hydroxypropyl)-7-methoxy-3-benzofurancarboxaldehyde | 62.78 | 0.4   |
|          | MOL007058| DS14 | formyltanshinone                                                                         | 73.44 | 0.42  |
|          | MOL007059| DS15 | 3-beta-Hydroxymethylenetanshinquinone                                                    | 32.16 | 0.41  |
|          | MOL007061| DS16 | Methylenebetanshinquinone                                                                | 37.07 | 0.36  |
|          | MOL007063| DS17 | przewalskin a                                                                           | 37.11 | 0.65  |
|          | MOL007064| DS18 | przewalskin b                                                                           | 110.32| 0.44  |
|          | MOL007066| DS19 | Przewaquinone b                                                                         | 62.24 | 0.41  |
|          | MOL007069| DS20 | przewaquinone c                                                                         | 55.74 | 0.4   |
|          | MOL007070| DS21 | (6S,7R)-6,7-dihydroxy-1,6-dimethyl-8,9-dihydro-7H-naphtho[8,7-g] benzofuran-10,11-dione | 41.31 | 0.45  |
|          | MOL007071| DS22 | przewaquinone f                                                                         | 40.31 | 0.46  |
|          | MOL007077| DS23 | sclareol                                                                                 | 43.67 | 0.21  |
|          | MOL007079| DS24 | tanshinaldehyde                                                                         | 52.47 | 0.45  |
|          | MOL007081| DS25 | Danshenol b                                                                             | 57.95 | 0.56  |
|          | MOL007082| DS26 | Danshenol a                                                                             | 56.97 | 0.52  |
|          | MOL007085| DS27 | Salvilenone                                                                              | 30.38 | 0.38  |
|          | MOL007088| DS28 | cryptotanshinone                                                                         | 52.34 | 0.4   |
|          | MOL007093| DS29 | dan-sheixinum d                                                                         | 38.88 | 0.55  |
|          | MOL007094| DS30 | danshenspiroketallactone                                                                 | 50.43 | 0.31  |
|          | MOL007098| DS31 | deoxyneocryptotanshinone                                                                  | 49.4  | 0.29  |
|          | MOL007100| DS32 | dihydrotanshinlactone                                                                    | 38.68 | 0.32  |
|          | MOL007101| DS33 | dihydrotanshinone I                                                                     | 45.04 | 0.36  |
|          | MOL007105| DS34 | epidanshenspiroketallactone                                                               | 68.27 | 0.31  |
|          | MOL007108| DS35 | isocryptotanshi-none                                                                     | 54.98 | 0.39  |
|          | MOL007111| DS36 | Isotanshinone II                                                                         | 49.92 | 0.4   |
|          | MOL007119| DS37 | miltionone I                                                                            | 49.68 | 0.32  |
|          | MOL007120| DS38 | miltionone II                                                                            | 71.03 | 0.44  |
|          | MOL007121| DS39 | multipolone                                                                              | 36.56 | 0.37  |
|          | MOL007122| DS40 | Miltirone                                                                                | 38.76 | 0.25  |
|          | MOL007124| DS41 | neocryptotanshinone II                                                                    | 39.46 | 0.23  |
AR, EGFR, ESR1, etc. These can be considered to be the core targets in the target interaction network of the Danshen-Guizhi drug pair for the treatment of ovarian cancer (Fig. 2).

In order to reveal the pharmacological mechanism of the Danshen-Guizhi drug pair in the treatment of ovarian cancer, the PPI of disease (Fig. 3A) and drug (Fig. 3B) were combined to obtain the intersection network (Fig. 3C). The degree value of all nodes was calculated according to the median of two times. All nodes with the degree value greater than two times the median were selected to extract the network, and the Hithubs1

| Medicine | MOL ID | Sign | Main active ingredient | OB(%) | DL(%) |
|----------|--------|------|------------------------|-------|-------|
| MOL007125 | DS42 | neocryptotanshinone | 52.49 | 0.32 |
| MOL007127 | DS43 | 1-methyl-8,9-dihydro-7H-naphtho[5,6-g] benzoferan-6,10,11-trione | 34.72 | 0.37 |
| MOL007130 | DS44 | proliothospermic acid | 64.37 | 0.31 |
| MOL007132 | DS45 | (2R)-3-(3,4-dihydroxyphenyl)-2-[(Z)-3-(3,4-dihydroxyphenyl) acryloyl] oxy-propionic acid | 109.38 | 0.35 |
| MOL007141 | DS46 | salvianolic acid g | 45.56 | 0.61 |
| MOL007143 | DS47 | salvilenone I | 32.43 | 0.23 |
| MOL007145 | DS48 | salviolone | 31.72 | 0.24 |
| MOL007150 | DS49 | (6S)-6-hydroxymethyl-6-methylol-8,9-dihydro-7H-naphtho[8,7-g] benzoferan-10,11-quinone | 75.39 | 0.46 |
| MOL007151 | DS50 | Tanshindiol b | 42.67 | 0.45 |
| MOL007152 | DS51 | Przewaquinone e | 42.85 | 0.45 |
| MOL007154 | DS52 | tanshinone ia | 49.89 | 0.4 |
| MOL007155 | DS53 | (6S)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7H-naphtho[8,7-g] benzoferan-10,11-dione | 65.26 | 0.45 |
| MOL007156 | DS54 | tanshinone VI | 45.64 | 0.3 |
| Guizhi | MOL001736 | GZ1 | (-)-taxifolin | 60.51 | 0.27 |
| MOL000358 | GZ2 | beta-sitosterol | 36.91 | 0.75 |
| MOL000359 | GZ3 | sitosterol | 36.91 | 0.75 |
| MOL000492 | GZ4 | (+)-catechin | 54.83 | 0.24 |
| MOL000073 | GZ5 | ent-Epicatechin | 48.96 | 0.24 |
| MOL004576 | GZ6 | taxifolin | 57.84 | 0.27 |

Figure 1 Venn diagram of active components of the Danshen-Guizhi drug pair and targets of ovarian cancer.

[![Ovarian cancer](Venn.png)](https://doi.org/10.7717/peerj.13148/fg-1)
**Figure 2** PPI network diagram. The greater the degree value, the larger the node and the darker the color.

**Figure 3** Screening of a core PPI network for Danshen-Guizhi drug pair in the treatment of ovarian cancer.
network (Fig. 3D) was obtained. The median and each attribute value of nodes in the Hithubs network were calculated. All nodes with the degree value greater than the median were selected to extract the network again, and the Hithubs2 network (Fig. 3E) was obtained. Finally, 70 key targets (Fig. 3F) were obtained.

Enrichment analysis of potential targets for the treatment of ovarian cancer by Danshen-Guizhi drug pair

The potential targets of Danshen-Guizhi drug pair in the treatment of ovarian cancer were input into Matescape database for analysis, and the limited type was “H. sapiens”. The personalized analysis was carried out, and the $P < 0.01$ was set. The enrichment analysis of potential targets of the Danshen-Guizhi drug pair in the treatment of ovarian cancer was obtained, as shown in Fig. 4. The biological processes of GO enrichment include: apoptotic signaling pathway, response to oxidative stress, response to reactive oxygen species, regulation of mitotic cell cycle, cellular response to lipid, response to organic cyclic compound and response to steroid hormone.

The results of KEGG enrichment analysis pathway were shown in Table 2. Pathways in cancer, hepatitis B, endocrine resistance, proteoglycans in cancer, AGE-RAGE signaling pathway in diabetes complications, PI3K-Akt signaling pathway, apoptosis, platinum drug resistance, TNF signaling pathway, IL-17 signaling pathway, progesterone-mediated oocyte maturation, and the prolactin signaling pathway were included in Fig. 5.
Construction of “component-target-pathway” network of Danshen-Guizhi drug pair

The results of effective active components, potential targets and enrichment pathways of the Danshen-Guizhi drug pair were analyzed by Cytoscape3.8.0 built-in plug-in CytoNCA, the core components and core targets of Danshen-Guizhi drug pair in the treatment of ovarian cancer were obtained, as shown in Fig. 6.

Cytoscape analysis results showed that the active ingredients DS7 luteolin, DS52 tanshinone IIA, DS48 salviolone, GZ2 beta-sitosterol, DS32 dihydrotanshinone lactone, DS28 cryptotanshinone and so on, among which the highest degree of luteolin was 58, the betweenness centrality was 0.204, and the closeness centrality was 0.476. It can be judged that luteolin was the core component of the Danshen-Guizhi drug pair in the treatment of ovarian cancer, followed by tanshinone (connectivity was 46, betweenness centrality was 0.048, and closeness centrality was 0.422), salviolone (connectivity was 39, betweenness centrality was 0.099, and closeness centrality was 0.414), and β-sitosterol (connectivity is 38, betweenness centrality was 0.083, closeness centrality was 0.431), which can be considered to be effective core components in the treatment of ovarian cancer.

The core target nodes were sorted by degree value (connectivity): PTGS2 (connectivity 61), CA2 (connectivity 46), NCOA1 (connectivity 33), HSP90AA1 (connectivity 31),

| GO      | Description                                         | LogP   | Count | Enrichment |
|---------|-----------------------------------------------------|--------|-------|------------|
| hsa05200 | Pathways in cancer                                   | −66.229| 27    | 35.521 46  |
| hsa05161 | Hepatitis B                                          | −44.160| 11    | 67.430 58  |
| hsa05169 | Epstein-Barr virus infection                         | −33.737| 93    | 37.065 88  |
| hsa01522 | Endocrine resistance                                 | −33.702| 80    | 88.803 66  |
| hsa05167 | Kaposi sarcoma-associated herpesvirus infection      | −32.865| 27    | 50.535 69  |
| hsa05163 | Human cytomegalovirus infection−                     | −32.508| 07    | 42.625 76  |
| hsa05166 | Human T-cell leukemia virus 1 infection              | −32.079| 13    | 36.123 52  |
| ko04933  | AGE-RAGE signaling pathway in diabetic complications  | −31.234| 36    | 81.807 01  |
| hsa05205 | Proteoglycans in cancer                              | −29.776| 68    | 43.016 82  |
| hsa05215 | Prostate cancer                                      | −28.844| 49    | 75.221 93  |
| hsa04151 | PI3K-Akt signaling pathway                           | −27.611| 97    | 26.921 53  |
| hsa04210 | Apoptosis                                            | −27.498| 32    | 53.635 06  |
| hsa01524 | Platinum drug resistance                             | −27.252| 35    | 93.426 32  |
| hsa05222 | Small cell lung cancer                               | −26.999| 62    | 73.195 75  |
| ko05166  | HTLV-1 infection                                     | −26.430| 33    | 34.966 44  |
| hsa05212 | Pancreatic cancer                                    | −26.360| 33    | 83.172 21  |
| hsa04668 | TNF signaling pathway                                | −25.812| 31    | 63.011 99  |
| ko04657  | IL-17 signaling pathway                              | −25.408| 17    | 73.334 64  |
| hsa04914 | Progesterone-mediated oocyte maturation              | −13.307| 95    | 41.384 23  |
| ko04917  | Prolactin signaling pathway                          | −13.149| 51    | 54.804 54  |

Qin et al. (2022), PeerJ, DOI 10.7717/peerj.13148
ADRB2 (connectivity 29), SCN5A (connectivity 29), PTGS1 (connectivity 29), CHRNA7 (connectivity 28), OPRM1 (connectivity 28), CHRM1 (connectivity 27), RXRA (connectivity 26), ESR1 (connectivity 25), F2 (connectivity 25), ADRA1A (connectivity 25), ACHE (connectivity 24), CHRM3 (connectivity 23), RELA (connectivity 21), DRD1 (connectivity 21), AR (connectivity 20), and NCOA2 (connectivity 20). According to the degree value, the above targets can be judged as effective core targets for the treatment of ovarian cancer, and PTGS2 is the main core target.

**Molecular docking analysis**

In AutoDock docking, the score of the binding ability between active ingredients and core targets of the Danshen-Guizhi drug pair was greater than 4.25, indicating that there was a binding ability between active ingredients and targets, greater than 5.25, indicating that the molecule has a good relationship with the target, and greater than 7.0, indicating that the molecule has an excellent binding ability to the target (Hsin, Ghosh & Kitano, 2013). The results of molecular docking analysis showed that the docking scores of salviolone and tanshinone IIA with the core targets were higher, and the docking scores of PTGS2, AR and PTGS1 with the active components were higher. In the total docking scores,
89% of the total docking scores were higher than 4.25, and 68% of the total docking scores were higher than 5.25, indicating that the predicted targets had good binding ability with the active components. The results of molecular docking were shown in Fig. 7. The higher the score was, the deeper the color was. The highest value was 8.16.
Inhibition of core components on ovarian cancer cells

The effects of luteolin, salviolone, β-sitosterol as well as tanshinone IIA on SKOV3 and A2780 cells were determined by MTS assay. Compared with the control group, the activity of SKOV3 cells (Fig. 8A) and A2780 cells (Fig. 8B) were significantly inhibited by 10 μm, 20 μm luteolin, salviolone, β-sitosterol as well as tanshinone IIA, as shown in Fig. 8.

Expression of PTGS2 mRNA and PGE2

The expression of PTGS2 mRNA was evaluated by qRT-PCR. The expression of PTGS2 in SKOV3 and A2780 cells were significantly inhibited by salviolone (Fig. 9A). The expression of PGE2 was determined by ELISA. The expression of PGE2 in SKOV3 cells was significantly down-regulated by salviolone (Fig. 9B).

DISCUSSION

This was the first study to explore the main effective components and potential mechanism of the Danshen-Guizhi drug pair in the treatment of ovarian cancer by network pharmacology. The “component-target-pathway” network of the Danshen-Guizhi drug pair was constructed to analyze the effective active components, important targets and potential mechanisms of the Danshen-Guizhi drug pair. Finally, the molecular docking and in vitro study were used to verify the network.

Four important active components were screened from the network of “component-target-pathway” of the Danshen-Guizhi drug pair, which were luteolin, salviolone, β-sitosterol and tanshinone IIA. Luteolin is a polyphenol flavonoids. Luteolin has anti-inflammatory, antiallergic, antioxidant and immuneregulatory pharmacological activities that can be used as antioxidants or prooxidants (Lin et al., 2008; Lopez-Lazaro, 2009; Wang et al., 2010).

| Component | PTGS2(5F19) | HSP90AA1(3WQ9) | PTGS1(1C9E) | ESR1(5ACC) | RELA(6NV2) | AR(2Q7K) | AKTI(1UNQ) |
|-----------|-------------|----------------|-------------|------------|------------|----------|------------|
| luteolin  | 8           | 6              | 8           | 4          | 6          | 8        | 6          |
| tanshinone IIA | 8       | 6              | 8           | 4          | 6          | 8        | 6          |
| salviolone | 8           | 6              | 8           | 4          | 6          | 8        | 6          |
| β-sitosterol | 8         | 6              | 8           | 4          | 6          | 8        | 6          |

Figure 7 Docking results of main components with core targets.

DOI: 10.7717/peerj.13148/fg-7

Qin et al. (2022), PeerJ, DOI 10.7717/peerj.13148
At the same time, luteolin has a strong role in cell apoptosis, cell cycle regulation, proliferation and differentiation of cancer cells (Tavsan & Kayali, 2019). Salviolone is an antioxidant component extracted from rosemary. Salviolone has many pharmacological effects such as anti-radiation, anti-oxidation, anti-cancer, and inhibiting the migration and invasion of cancer cells (Zhang, Li & Ji, 2018). Beta-sitosterol, a plant derived nutrient, studies have shown that β-sitosterol can interfere with a variety of cell signaling pathways,
including apoptosis, cell proliferation and angiogenesis, metastasis and inflammation (Bin Sayeed & Ameen, 2015). Tanshinone IIA is an active component extracted from Danshen. Tanshinone IIA can induce apoptosis of ovarian cancer TOV-21G cells by up-regulating miR-205, which mainly reveals the potential therapeutic application of tanshinone IIA in ovarian cancer (Li et al., 2018). In vitro experiments showed that the activity of SKOV3 and A2780 cells were significantly inhibited by luteolin, salviolone, β-sitosterol and tanshinone IIA. This indicated that the Danshen-Guizhi drug pair might treat ovarian cancer through these components.

By analyzing the “component-target-pathway” network of the Danshen-Guizhi drug pair, the main selected targets were PTGS2, HSP90AA1, PTGS1, AKT1 and ESR1. PTGS2 enhanced the proliferation and migration of human ovarian cancer CAOV-3 cells mainly by activating phosphatidylinositol 3 kinase/protein kinase B (PI3-k/Akt) pathway (Gu et al., 2008). It was reported that HSP90AA1 could affect the survival of tumor cells, the invasion and migration of cancer cells, and was closely related to the poor prognosis of tumours. HSP90AA1 RNAi could inhibit the proliferation of ovarian cancer SKOV3 cells and increase its apoptosis (Calderwood et al., 2006; Chu et al., 2013). AKT1 (AKT) is a serine/threonine-specific protein kinase. The activation of PI3K/AKT target caused about 70% of ovarian cancer cells to be activated, which made many signaling pathways related to cell growth, proliferation, survival, metabolism and angiogenesis overactive (Li, Zeng & Shen, 2014). ESR1 is an important component of estrogen receptor. It is generally believed that ESR1 regulated the expression of protein-coding genes closely related to cell proliferation, survival, differentiation, and participation in the process of cancer (Hu, Chen & Ding, 2018). Therefore, it can be speculated that the Danshen-Guizhi drug pair mainly plays biological functions in the treatment of ovarian cancer through the above targets.

Based on the enrichment results and the analysis of the Danshen-Guizhi drug pair “component-target-pathway” network, it can be considered that the main biological processes are apoptosis, cell proliferation and tumor immunity. The main active components involved were luteolin, salviolone, β-sitosterol and tanshinone IIA.

The pathways involved in apoptosis are mainly apoptosis pathway and PI3K-Akt signaling pathway. PI3K-Akt signal transduction is usually destroyed in human cancer, and AKT1 is an important part of this pathway, which affects multiple processes directly involved in tumorigenesis (Brown & Banerji, 2017). AKT1, CCND1, EGFR, HSP90AA1, MAPK1, RELA and TP53 are involved in the PI3K-Akt signal pathway. The main pathways involved in cell proliferation are PI3K-Akt signaling pathway and proteoglycan pathway in cancer. As an important macromolecule, proteoglycans can participate in the biological process of various cancers and plays an important role. It can affect the progression of tumors by affecting the proliferation, angiogenesis and metastasis of tumor cells (Goldoni et al., 2008). AKT1, CCND1, CASP3, CDKN1A, ESR1, MAPK1, TP53 and other proteins participate in the proteoglycan pathway in cancer. The main pathway involved in tumor immunity is IL-17 signaling pathway. IL-17A is a multi-effect cytokine, and its expression is related to the pathological differentiation level and lymph node.
metastasis of ovarian cancer patients (Wang et al., 2020). CASP3, HSP90AA1, MAPK1, PTGS2, MAPK1 and TP53 are involved in this pathway.

PTGS2 and PGE2 could promote cancer progression by affecting the differentiation and survival of tumor-associated immune cells, and shifting the tumor microenvironment into an immunosuppressive environment (Wang & Dubois, 2010). PTGS2 and PGE2 inhibition may be useful to augment cancer immunotherapy (Chen & Smyth, 2011). In our study, in vitro cell experiments showed that the expression of PTGS2 in SKOV3 cells as well as A2780 cells and PGE2 in SKOV3 cells were significantly inhibited by salviolone. This further indicates the mechanism of the Danshen-Guizhi drug pair in the treatment of ovarian cancer may be inhibiting the expression of PTGS2.

CONCLUSION

In summary, the effective components of the Danshen-Guizhi drug pair in the treatment of ovarian cancer may be salviolone, luteolin, β-sitosterol and tanshinone IIA. The most effective target is PTGS2. The potential mechanism of the Danshen-Guizhi drug pair in the treatment of ovarian cancer may be regulating the proliferation, apoptosis and tumor immunity. This can provide a theoretical basis for the future application of the Danshen-Guizhi drug pair in the treatment of ovarian cancer, and also provide a reference for the clinical application of the Danshen-Guizhi drug pair. Our results need to be validated by further researches.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by foundation projects: National natural science foundation of China (No. 81703780); Science and Technology Project of Henan Province (Nos. 212102310348; 212102310357); and Key Research and Development Program of Hunan Province (Grant No. 2018SK2121). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
National Natural Science Foundation of China: 81703780.
Science and Technology Project of Henan Province: 212102310348; 212102310357.
Key Research and Development Program of Hunan Province: 2018SK2121.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Chongzhen Qin conceived and designed the experiments, prepared figures and/or tables, authored or reviewed drafts of the paper, and approved the final draft.
- Menglin Wu conceived and designed the experiments, prepared figures and/or tables, and approved the final draft.
Xinru Wang performed the experiments, prepared figures and/or tables, and approved the final draft.

Wenda Zhang performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Guangzhao Qi analyzed the data, prepared figures and/or tables, and approved the final draft.

Na-Yi Wu analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.

Xiaoting Liu performed the experiments, prepared figures and/or tables, and approved the final draft.

Yaoyao Lu analyzed the data, prepared figures and/or tables, and approved the final draft.

Jingmin Zhang conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.

Yuna Chai performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Data Availability
The following information was supplied regarding data availability:

The raw measurements are available in the Supplemental File.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.13148#supplemental-information.

REFERENCES
Bin Sayeed MS, Ameen SS. 2015. Beta-Sitosterol: a promising but orphan nutraceutical to fight against cancer. Nutrition and Cancer 67(8):1214–1220 DOI 10.1080/01635381.2015.1087042.

Brown JS, Banerji U. 2017. Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacology & Therapeutics 172:101–115 DOI 10.1016/j.pharmthera.2016.12.001.

Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. 2006. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends in Biochemical Sciences 31(3):164–172 DOI 10.1016/j.tibs.2006.01.006.

Chen EP, Smyth EM. 2011. COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins & Other Lipid Mediators 96(1–4):14–20 DOI 10.1016/j.prostaglandins.2011.08.005.

Chu S-H, Liu Y-W, Zhang L, Liu B, Li L, Shi J-Z, Li L. 2013. Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Molecular Biology Reports 40(1):1–6 DOI 10.1007/s11033-012-1930-3.

Gaona-Luviano P, Medina-Gaona LA, Magana-Perez K. 2020. Epidemiology of ovarian cancer. Chinese Clinical Oncology 9(4):47 DOI 10.21037/cco20-34.

Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV. 2008. An antimetastatic role for decorin in breast cancer. The American Journal of Pathology 173(3):844–855 DOI 10.2353/ajpath.2008.080275.
Gu P, Su Y, Guo S, Teng L, Xu Y, Qi J, Gong H, Cai Y. 2008. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Investigation 26(8):822–829 DOI 10.1080/07357900801941860.

Hsin KY, Ghosh S, Kitano H. 2013. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLOS ONE 8(12):e83922 DOI 10.1371/journal.pone.0083922.

Hu HB, Chen Q, Ding SQ. 2018. LncRNA LINC01116 competes with miR-145 for the regulation of ESR1 expression in breast cancer. European Review for Medical and Pharmacological Sciences 22(7):1987–1993 DOI 10.26355/eurrev_201804_14726.

Hunn J, Rodriguez GC. 2012. Ovarian cancer: etiology, risk factors, and epidemiology. Clinical Obstetrics and Gynecology 55(1):3–23 DOI 10.1097/GRF.0b013e31824b4611.

Jiang YG, Lin HS. 2006. Current status of traditional Chinese medicine in the treatment of ovarian cancer. Journal of Practical Oncology 20(3):235–238 DOI 10.3969/j.issn.1002-3070.2006.03.034.

Jiao JW, Wen F. 2011. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncology Reports 25(3):781–788 DOI 10.3892/or.2010.1107.

Lee WY, Lee CY, Kim YS, Kim CE. 2019. The methodological trends of traditional herbal medicine employing network pharmacology. Biomolecules 9(8):632 DOI 10.3390/biom9080362.

Li N, Yang L, Zhang B, Chen S. 2018. Tanshinone IIA effects on ovarian cancer cell line. Journal of Pharmacy and Pharmacology 70(10):1369–1377 DOI 10.1111/jphp.12961.

Li HX, Zeng JF, Shen K. 2014. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Archives of Gynecology and Obstetrics 290(6):1067–1078 DOI 10.1007/s00404-014-3377-3.

Li S, Zhang B. 2013. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chinese Journal of Natural Medicines 11(2):110–120 DOI 10.3724/SP.J.1009.2013.00110.

Lin Y, Shi R, Wang X, Shen HM. 2008. Luteolin, a flavonoid with potential for cancer prevention and therapy. Current Cancer Drug Targets 8(7):634–646 DOI 10.2174/15680908786241050.

Liu J, Mu J, Zheng C, Chen X, Guo Z, Huang C, Fu Y, Tian G, Shang H, Wang Y. 2016. Systems-pharmacology dissection of traditional chinese medicine compound saffron formula reveals multi-scale treatment strategy for cardiovascular diseases. Scientific Reports 6:19809 DOI 10.1038/srep19809.

Liu H, Wang J, Zhou W, Wang Y, Yang L. 2013. Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. Journal of Ethnopharmacology 146(3):773–793 DOI 10.1016/j.jep.2013.02.004.

Liu J, Zhang Q, Li RL, Wei SJ, Huang CY, Gao YX. 2020. The traditional uses, phytochemistry, pharmacology and toxicology of Cinnamomi ramulus: a review. Journal of Pharmacy and Pharmacology 72(3):319–342 DOI 10.1111/jphp.13189.

Lopez-Lazaro M. 2009. Distribution and biological activities of the flavonoid luteolin. Mini-Reviews in Medicinal Chemistry 9(1):31–59 DOI 10.2174/138955709787001712.

Mao Y, Hao J, Jin ZQ, Niu YY, Yang X, Liu D, Cao R, Wu X-Z. 2017. Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients. Oncotarget 8(16):27007–27021 DOI 10.18632/oncotarget.15351.

McMullen M, Madariaga A, Lheureux S. 2020. New approaches for targeting platinum-resistant ovarian cancer. Seminars in Cancer Biology 77:167–181 DOI 10.1016/j.semcancer.2020.08.013.
Reddy ND, Shoja MH, Biswas S, Nayak PG, Kumar N, Rao CM. 2016. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells. *Chemico-Biological Interactions* 253(34):112–124 DOI 10.1016/j.cbi.2016.05.008.

Ren W, Luo Z, Pan F, Liu J, Sun Q, Luo G, Wang R, Zhao H, Bian B, Xiao X, Pu Q, Yang S, Yu G. 2020. Integrated network pharmacology and molecular docking approaches to reveal the synergistic mechanism of multiple components in *Venenum Bufonis* for ameliorating heart failure. *PeerJ* 8:e10107 DOI 10.7717/peerj.10107.

Su CY, Ming QL, Rahman K, Han T, Qin LP. 2015. *Salvia miltiorrhiza*: traditional medicinal uses, chemistry, and pharmacology. *Chinese Journal of Natural Medicines* 13(3):163–182 DOI 10.1016/S1875-5364(15)30002-9.

Sun J, Liu J, Liu D, Wu X. 2020. Network pharmacology-based and clinically relevant prediction of the potential targets of chinese herbs in ovarian cancer patients. *Biomed Research International* 2020:8965459 DOI 10.1155/2020/8965459.

Tavsan Z, Kayali HA. 2019. Flavonoids showed anticancer effects on the ovarian cancer cells: Involvement of reactive oxygen species, apoptosis, cell cycle and invasion. *Biomedicine & Pharmacotherapy* 116:109004 DOI 10.1016/j.biopharma.2019.109004.

Wang D, Dubois RN. 2010. Eicosanoids and cancer. *Nature Reviews Cancer* 10(3):181–193 DOI 10.1038/nrc2809.

Wang H, Luo Y, Qiao T, Wu Z, Huang Z. 2018. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion. *Journal of Ovarian Research* 11(1):93 DOI 10.1186/s13048-018-0468-y.

Wang X, Xu X, Jiang G, Zhang C, Liu L, Kang J, Wang J, Owusu L, Zhou L, Zhang L, Li W. 2020. Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene. *Journal of Cellular and Molecular Medicine* 24(19):11177–11187 DOI 10.1111/jcmm.15660.

Wang L, Zhang X, Wang L, Wang B, Zhang J, Li Y. 2020. IL-17A/IL-17RA reduces cisplatin sensitivity of ovarian cancer SKOV3 cells by regulating autophagy. *Nan Fang Yi Ke Da Xue Xue Bao* 40(11):1550–1556 DOI 10.12122/j.issn.1673-4254.2020.11.03.

Yang Y, Cao Y, Chen L, Liu F, Qi Z, Cheng X, Wang Z. 2018. Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3/SIRT3 signaling pathway in ovarian cancer cells. *Cancer Medicine* 7(9):4610–4618 DOI 10.1002/cam4.1691.

Zhang GB, Li QY, Chen QL, Su SB. 2013. Network pharmacology: a new approach for chinese herbal medicine research. *Evidence-Based Complementary and Alternative Medicine* 2013(8):621423–621429 DOI 10.1155/2013/621423.

Zhang YN, Li GX, Ji C. 2018. Inhibition of human cervical cancer cell growth by Salviolone is mediated via autophagy induction, cell migration and cell invasion suppression, G2/M cell cycle arrest and downregulation of Nf-kb/m-TOR/PI3K/AKT pathway. *Journal of the Balkan Union of Oncology* 23(6):1739–1744.

Zhou Z, Chen B, Chen S, Lin M, Chen Y, Jin S, Chen W, Zhang Y. 2020. Applications of network pharmacology in traditional chinese medicine research. *Evidence-Based Complementary and Alternative Medicine* 2020(06):1646905–1646907 DOI 10.1155/2020/1646905.

Zhou J, Jiang YY, Chen H, Wu YC, Zhang L. 2020. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. *Cell Proliferation* 53(2):e12739 DOI 10.1111/cpr.12739.